- Home
- FHTX
as 07-26-2024 4:00pm EST
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 326.4M | IPO Year: | 2020 |
| Target Price: | $13.00 | AVG Volume (30 days): | 137.2K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $9.97 | Next Earning Date: | 08-02-2024 |
| Revenue: | $33,896,000 | Revenue Growth: | 64.41% |
| Revenue Growth (this year): | -15.21% | Revenue Growth (next year): | 8.63% |
Stock Insider Trading Activity of Foghorn Therapeutics Inc. (FHTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cavalie Fanny | FHTX | Chief Strategy/Bus Ops Officer | Mar 11 '24 | Sell | $6.56 | 11,000 | $72,133.60 | 75,992 | SEC Form 4 |
Latest Foghorn Therapeutics Inc. News
FHTX Breaking Stock News: Dive into FHTX Ticker-Specific Updates for Smart Investing
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
CNW Group
a month ago
**Canadian Interest in American Whiskey Peaks Ahead of Bourbon Day**
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
Motley Fool
a month ago
Where Will DocuSign Stock Be in 1 Year?
Reuters
a month ago
Spotify to introduce expensive plan later this year, Bloomberg News reports
GlobeNewswire
a month ago
Poppulo Joins Elite Category in BrightSign Bright Alliance Program, Announces Certification Across Series 5 Devices
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Business Wire
a month ago
Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
Compare FHTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FHTX Foghorn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.